Suubi4Stigma: Addressing HIV-associated stigma among adolescents
Principal Investigator: Proscovia Nabunya, PhD; Fred M. Ssewamala, PhD
Project Team Members: James Mugisha, PhD; Ozge Sensoy Bahar, PhD; Jean-Francois Trani, PhD
Field Coordinator: Raymond Atwebembere
Research Collaborators: Abel Mwebembezi (Reach the Youth-Uganda)
This three-arm pilot randomized clinical trial will be conducted across 9 health clinics in the greater Masaka region of Uganda. Clinics will be randomized to one of three study arms (n=3 clinics; 30 child-caregiver dyads each arm): 1) Usual care to receive the currently implemented usual care addressing HIV/AIDS-associated stigma (educational materials from the Uganda Ministry of Health); 2) G-CBT intervention + Usual care; and 3) MFG intervention + Usual care.
Intervention Sessions and Duration:
G-CBT sessions will be facilitated by trained para-counselors and will include no more than 10 participants (children only) per group. The 10 sessions will be delivered twice per week outside of school hours and will last approximately 1 hour each. G-CBT sessions will focus on the exploration of HIV’s role and impact of stigma in adolescent’s life; use of cognitive restructuring to identify and address the negative stigma-associated beliefs, loss of self-worth, self-blame; and skill-building around stress management and emotion-focused coping strategies to address negative feelings (e.g. assertiveness, relaxation skills and problem solving skills).
MFG sessions will be delivered by trained community health workers and parent peers, with 10 families (child and caregiver/family member) per group. Session content will focus on HIV and stigma, and the core components of MFG, also known as 4Rs and 2S’s (rules, responsibility, relationships, respectful communication, stress and social support). MFG sessions (10 sessions in total) will last approximately 1 hour and will be delivered twice a week, outside of school hours.
Both treatment and usual care arms will be delivered over a 3-month period. Participants will be followed over a 6-month period, with data collected at baseline, 3 months and 6 months post intervention initiation.